U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023432) titled 'Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)' on June 10.
Brief Summary: To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not undergone previous systemic treatment. The safety of belzutifan in this patient population will also be studied.
Study Start Date: Dec. 03, 2025
Study Type: INTERVENTIONAL
Condition:
Active Surveillance
Clear Cell Renal Cell Carcinoma
Intervention:
DRUG: Belzutifan
Given by PO
OTHER: Active Surveillance
Given by Observati...